Free Trial

DexCom (DXCM) Stock Price, News & Analysis

$130.88
+0.04 (+0.03%)
(As of 09:39 AM ET)
Today's Range
$130.28
$130.88
50-Day Range
$124.34
$140.45
52-Week Range
$74.75
$142.00
Volume
33,075 shs
Average Volume
2.87 million shs
Market Capitalization
$52.05 billion
P/E Ratio
84.44
Dividend Yield
N/A
Price Target
$141.67

DexCom MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
8.3% Upside
$141.67 Price Target
Short Interest
Healthy
2.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.94mentions of DexCom in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$25.22 M Sold Last Quarter
Proj. Earnings Growth
25.28%
From $1.78 to $2.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.83 out of 5 stars

Medical Sector

42nd out of 921 stocks

Surgical & Medical Instruments Industry

10th out of 97 stocks

DXCM stock logo

About DexCom Stock (NASDAQ:DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Stock Price History

DXCM Stock News Headlines

DXCM May 2024 133.000 put
DexCom (NASDAQ:DXCM) Upgraded to "Buy" at StockNews.com
DexCom First Quarter 2024 Earnings: Beats Expectations
DexCom, Inc. (DXCM) Q1 2024 Earnings Call Transcript
Q1 2024 Dexcom Inc Earnings Call
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/25/2024
Today
5/21/2024
Next Earnings (Estimated)
7/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
Employees
9,600
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$141.67
High Stock Price Target
$165.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+8.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Net Income
$541.50 million
Pretax Margin
20.48%

Debt

Sales & Book Value

Annual Sales
$3.62 billion
Cash Flow
$2.06 per share
Book Value
$5.35 per share

Miscellaneous

Free Float
396,491,000
Market Cap
$52.03 billion
Optionable
Optionable
Beta
1.23

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

DXCM Stock Analysis - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings
or view top-rated stocks.

What is DexCom's stock price target for 2024?

14 brokers have issued 12 month target prices for DexCom's shares. Their DXCM share price targets range from $100.00 to $165.00. On average, they predict the company's stock price to reach $141.67 in the next year. This suggests a possible upside of 8.3% from the stock's current price.
View analysts price targets for DXCM
or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2024?

DexCom's stock was trading at $124.09 at the beginning of 2024. Since then, DXCM shares have increased by 5.4% and is now trading at $130.84.
View the best growth stocks for 2024 here
.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our DXCM earnings forecast
.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) announced its earnings results on Thursday, April, 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The medical device company had revenue of $921 million for the quarter, compared to analysts' expectations of $911.20 million. DexCom had a trailing twelve-month return on equity of 31.01% and a net margin of 16.82%.
Read the conference call transcript
.

When did DexCom's stock split?

DexCom's stock split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its FY 2024 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.22%), Baillie Gifford & Co. (3.94%), Capital Research Global Investors (3.38%), Capital World Investors (2.03%), Blair William & Co. IL (1.14%) and Price T Rowe Associates Inc. MD (0.74%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends
.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does DexCom have any subsidiaries?
The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More
This page (NASDAQ:DXCM) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners